GLP-1 receptor agonists have revolutionized weight management and diabetes care. However, their mechanism of action—significantly reducing appetite and slowing gastric emptying—presents a unique challenge in Long-Term Care (LTC) settings. When caloric intake drops precipitously, the body metabolizes both fat and muscle for energy. Clinical data indicates that 30-39% of the weight lost on GLP-1 medications is lean muscle mass.
In an LTC population, muscle loss (sarcopenia) is already a critical concern. Accelerated muscle depletion increases the risk of falls, frailty, and loss of independence. For Canadian facility operators, managing the nutritional needs of residents on these medications is no longer optional; it is a fundamental requirement of care.







